Monday’s Midday Stock Update: Brainstorm Cell Therapeutics (BCLI), Aerie Pharma (AERI), Intercept Pharma (ICPT), SunPower (SPWR), Cleveland-Cliffs (CLF)

By Carrie Williams

So far Monday, October 19, NASDAQ is down -5.75% and the S&P is down -3.7%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Brainstorm Cell Therapeutics (BCLIResearch Report), Aerie Pharma (AERIResearch Report), Intercept Pharma (ICPTResearch Report), SunPower (SPWRResearch Report) and Cleveland-Cliffs (CLFResearch Report).

Brainstorm Cell Therapeutics is down -8.29% in midday trading to $12.84. Shares opened today at $14.00. The company has a 52-week low of $3.58 and a 52-week high of $17.95. On the Street’s front, the average 12-month analyst price target for the stock is $20.00, marking a 42.86% potential upside from current levels. In a report issued on October 15, Maxim Group analyst Jason McCarthy assigned a Buy rating on BCLI, with a price target of $20.00, which implies an upside of 43% from current levels.

Aerie Pharma is down -7.45% in midday trading to $10.18. Shares opened today at $11.00. The company has a 52-week low of $10.22 and a 52-week high of $26.26. On the Street’s front, the average 12-month analyst price target for the stock is $24.25, marking a 120.45% potential upside from current levels. In a report released today, Merrill Lynch analyst Jason Gerberry downgraded AERI to Sell, with a price target of $9.00, which represents a potential downside of 18% from where the stock is currently trading. Separately, on October 16, Needham’s Serge Belanger assigned a Buy rating to the stock and has a price target of $26.00.

Intercept Pharma is down -7.03% in midday trading to $32.69. Shares opened today at $35.16. The company has a 52-week low of $33.25 and a 52-week high of $125.00. On the Street’s front, the average 12-month analyst price target for the stock is $76.82, marking a 118.49% potential upside from current levels. In a report issued on October 13, Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on ICPT, with a price target of $82.00, which represents a potential upside of 133% from where the stock is currently trading. Separately, on October 8, BMO’s Matthew Luchini maintained a Hold rating on the stock and has a price target of $56.00. Over the last 3 months, the insider sentiment on Intercept Pharma has been negative based on 99 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

SunPower is up 6.08% in midday trading to $18.33. Shares opened today at $17.28. The company has a 52-week low of $4.03 and a 52-week high of $18.25. On the Street’s front, the average 12-month analyst price target for the stock is $13.42, marking a -22.34% potential downside from current levels. In a report issued on October 16, Goldman Sachs analyst Brian K. Lee maintained a Buy rating on SPWR, with a price target of $19.00, which implies an upside of 10% from current levels. Separately, on September 30, Oppenheimer’s Colin Rusch maintained a Hold rating on the stock . Over the last 3 months, the insider sentiment on SunPower has been negative based on 60 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Cleveland-Cliffs is up 5.1% in midday trading to $8.03. Shares opened today at $7.64. The company has a 52-week low of $2.63 and a 52-week high of $9.02. On the Street’s front, the average 12-month analyst price target for the stock is $5.82, marking a -23.82% potential downside from current levels. In a report issued on September 29, Citigroup analyst Alexander Hacking maintained a Hold rating on CLF. Separately, on September 14, B.Riley Financial’s Lucas Pipes reiterated a Buy rating on the stock and has a price target of $10.00. In the last 30 days, insiders have sold $8,998 worth of CLF shares and purchased $71.44K worth of CLF shares.

See today’s analyst top recommended stocks >>

Trending Stocks Based on Insider Activity >>